NASDAQ
Total Transactions
7
0 buys /7 sells
Shares Acquired
0
Transactions: 0•Avg: 0
Shares Disposed
25,858
Transactions: 7•Avg: 3,694
Net Activity
-25,858
Net Selling•Ratio: 0%
Q4 2025(Current) | 0 | 25,858 | -25,858 | 0.00% |
Q3 2025 | 10,700 | 17,417 | -6,717 | 40.00% |
Q2 2025 | 97,933 | 38,514 | +59,419 | 280.00% |
Q1 2025 | 492,146 | 318,593 | +173,553 | 68.00% |
Q4 2024 | 19,500 | 929 | +18,571 | 100.00% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q4 2025
Acquired vs Disposed Shares
Net Distribution: 25,858 shares•Acquired/Disposed Ratio: 0%
Net Activity | |||||
|---|---|---|---|---|---|
CKT Conroy Kevin T | Director, officer: president and ceo | 24 | 289,777 | 229,069 | +60,708 |
BA Bloomer Aaron | Officer: evp, chief financial officer | 7 | 53,239 | 35,307 | +17,932 |
CS Condella Sarah | Officer: evp, human resources | 11 | 35,509 | 18,244 | +17,265 |
BB Baranick Brian | Officer: evp, gm, precision oncology | 14 | 47,756 | 31,473 | +16,283 |
TL Trigg Leslie | Director | 3 | 16,197 | 0 | +16,197 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2025-11-19 | Officer: evp, gm, screening | Sale | 5,000 | $75 | $375,000 | 23,237 | |
2025-11-19 | Officer: svp, general counsel & sec | Sale | 1,000 | $70 | $70,000 | 11,585 | |
2025-11-04 | Officer: svp, general counsel & sec | Sale | 1,500 | $70.08 | $105,120 | 12,585 | |
2025-11-04 | Officer: evp, gm, precision oncology | Sale | 2,858 | $70.08 | $200,288.64 | 22,368 | |
2025-10-24 | Director | Sale | 12,000 | $65 | $780,000 | 60,759 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
OJA ORVILLE JACOB A | Officer: evp, gm, screening | Nov 21, 2025 | |
HJ Herriott James | Officer: svp, general counsel & sec | Nov 21, 2025 | |
HJ Herriott James | Officer: svp, general counsel & sec | Nov 6, 2025 | |
BB Baranick Brian | Officer: evp, gm, precision oncology | Nov 6, 2025 | |
ZKS Zanotti Katherine S | Director | Oct 27, 2025 |
Net change in shares shown on right
No price data available for this timeframe.